CHINA STARCH (03838) announced on August 24 that it spent approximately HKD 469,600 to repurchase 2.895 million shares.
China Starch (03838) announced that on August 24, 2026, the company spent approximately HKD 469,600 to repurchase 2.895 million shares, with the repurchase price ranging from HKD 0.161 to HKD 0.163 per share.
CHINA STARCH (03838) announced that on August 24, 2026, the company invested approximately HKD 469,600 to repurchase 2.895 million shares, with the repurchase price ranging from HKD 0.161 to HKD 0.163 per share.
Related Articles
BAO PHARMA-B (02659): The clinical trial application for KJ015 injection (anti-HER2 bispecific antibody subcutaneous formulation) has been approved by the US FDA.
EPI (HOLDINGS)(00689) issues a profit warning, expecting an interim loss attributable to shareholders of no more than HKD 16 million.
BABA-W (09988) awarded 1,932,300 related shares as a reward.
BAO PHARMA-B (02659): The clinical trial application for KJ015 injection (anti-HER2 bispecific antibody subcutaneous formulation) has been approved by the US FDA.
EPI (HOLDINGS)(00689) issues a profit warning, expecting an interim loss attributable to shareholders of no more than HKD 16 million.
BABA-W (09988) awarded 1,932,300 related shares as a reward.
RECOMMEND
